The October 2026 issue of the Journal of the American Academy of Dermatology carries an assessor-blinded, randomized, split-face comparison of a 532 nm potassium titanyl phosphate (KTP) laser against intense pulsed light (IPL) for keratosis pilaris rubra (KPR), the erythematous variant of a follicular keratinization disorder (a condition in which excess keratin plugs the hair follicle).

The brief report occupies pages 1160 to 1162 of Volume 95, Issue 4, with Jiong Zhou and Xiaoqing Dong listed as co-first authors and Mengjun Xu as senior author. Four co-investigators join them: Yanjun Chu, Suiqing Cai, Xibei Chen, and Xu himself. The trial carries institutional review board approval #2024-0842 from the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine.

What endpoints does the trial measure?

The published keywords list erythema and roughness as the outcomes of interest, with KPR, KTP laser, intense pulsed light, and split-face trial as the methodological descriptors. Effect sizes, sample size, treatment session count, follow-up interval, and adverse events do not appear in the available metadata. Readers seeking those numbers will need the full text, which ScienceDirect has not released as open access at the time of writing.

Why these two devices?

KTP lasers emit green light at 532 nm, a wavelength preferentially absorbed by oxyhemoglobin (the oxygen-bound form of hemoglobin in red blood cells). Bernstein and colleagues reported a 532 nm KTP system for lower-extremity spider veins in 2014, establishing the wavelength's track record against superficial vascular targets. KPR presents as persistent pink-to-red erythema across the lateral cheeks, sometimes extending to the upper arms and trunk, with follicular plugging and a sandpaper-like texture. Marqueling and colleagues in 2006 characterized KPR as "common but underrecognized," and the present authors appear to have taken that framing as their rationale.

What is the design?

The trial is assessor-blinded, meaning the clinician grading outcomes did not know which side of each face received which device. Split-face protocols assign one device to each hemiface of the same patient, removing between-subject variability (the natural differences from one person to the next) as a confounding factor. The authors disclosed no conflicts of interest. The work received support from the National Natural Science Foundation of China under grants 82003332 and 82073425.

What should practitioners weigh?

The available record contains no quoted investigator statement. Dermatology readers will need the full text to see whether IPL or KTP delivered the larger reduction in erythema, whether roughness improved symmetrically or asymmetrically, and whether adverse events such as post-inflammatory hyperpigmentation (darkening of skin after inflammation) or pinpoint scarring emerged on either hemiface.

Split-face cosmetic trials raise a recurring concern: the brief report does not specify whether the protocol used a single session or multiple sessions. For vascular laser work, single-pass and multi-pass protocols can yield meaningfully different clinical results. Until that detail emerges, the practical translation of these findings remains provisional.

The funding profile warrants attention as well. Both grants listed come from the Chinese National Natural Science Foundation, and no industry sponsor appears among the disclosures. The absence of a manufacturer partner is a small but real signal that the comparison was investigator-initiated rather than device-driven.

What is the forward implication?

If the 532 nm KTP arm outperforms IPL on the erythema endpoint — the larger of KPR's two clinical burdens — operators already using KTP platforms for rosacea and facial telangiectasias (small dilated surface blood vessels) could add KPR to their case mix without new capital expenditure. The brief report establishes the architecture of that comparison. The magnitude of any benefit, and the durability of any roughness reduction, will emerge in the full text and in any subsequent replication.